New funding for Global Health Product Development Partnerships
FCDO has partnered with public-private Product Development Partnerships (PDPs) for more than 20 years to develop new medicines, vaccines and diagnostics for diseases and settings where commercial markets do not deliver. During 2024, FCDO conducted an international competitive call for proposals for Product development research for global health for funding during 2025–2028.
As announced by Minister for Development Baroness Chapman on 18 May 2026 (see press release), ten organisations have now been awarded funding and are supported by GRTD to develop new technologies for sexual and reproductive health, infectious diseases of poverty, and diseases with epidemic and pandemic potential.
FCDO supports end-to-end partnerships with clear equitable access plans built into their R&D, and with operations increasingly centred in the countries most affected. These new awards, which began between November 2024 and September 2025, will run until March 2028. They are:
• Medicines for Malaria Venture (MMV) – developing new drugs to prevent and treat malaria.
• TB Alliance (TBA) – developing new medicines and treatment regimens for tuberculosis.
• Drugs for Neglected Diseases initiative (DNDi) – developing life-saving treatments for neglected tropical diseases, including sleeping sickness and leishmaniasis.
• Innovative Vector Control Consortium (IVCC) – developing new vector control technologies, including mosquito nets.
• Programme for Appropriate Technology in Health (PATH) – expanding vaccine access, developing new syphilis diagnostics, and testing treatments for post-partum haemorrhage.
• Centre for Biomedical Research (CBR) at Population Council – developing next-generation contraceptive methods and vaginal ring technologies for contraceptive and antiretroviral use.
• International Vaccine Institute (IVI) – discovering and developing safe, effective and affordable vaccines, including for cholera.
• World Mosquito Program – advancing novel approaches to vector control.
• Liverpool School of Tropical Medicine’s ‘ENDPOINT’ programme– advancing new solutions for eliminable parasitic diseases spread by insects, including lymphatic filariasis.
• King’s College’s ‘Cradle Smart’ programme – developing low-cost, accessible point-of-care diagnostics for post-partum haemorrhage and pre-eclampsia in LMIC settings.
See more
The Frontier Tech Hub is launching OASIS: a shared, open platform for AI in development. It’s a place to find tools other people have built, discuss what’s working, and build on it rather than starting again.
Beyond the Axis is part of the Cross-border Conflict Evidence Policy and Trends (XCEPT) programme. The project set out to understand how Iranian arms transfers to allied groups has changed over time, and was ultimately able to explain how and why Iran, and its ‘Axis of Resistance’ allies have proven more resilient than expected in the wake of the regional crises since October 2023.
TEA is the flagship FCDO research and innovation platform supporting early-stage testing and scale up of innovative clean energy technologies and business models in developing countries, targeting the 655 million people still without access to electricity.
How can social protection better deliver for the most marginalised women and girls? Research from the Gender-Responsive Social Protection programme (GSP) offers important answers.